Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies
Authors:
- 14 July 2023
- journal article
- review article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 30 (5) , 829-843
Abstract
The recent approval of new medications with novel mechanisms of action and emergence of updated safety information for existing therapies has changed the treatment landscape of inflammatory bowel disease (IBD). These advances led to unique adverse effect profiles and identification of new safety signals, resulting in the evolution of the safety, monitoring, and positioning of IBD therapies. In this updated review, we (1) examine the existing and updated safety data of monoclonal antibodies and small molecules for IBD, with a focus on recently Food and Drug Administration (FDA)-approved therapies, and (2) propose risk stratification and assessment considerations prior to and during IBD treatment.Keywords
This publication has 96 references indexed in Scilit:
- Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor AgentsClinical Gastroenterology and Hepatology, 2016
- Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and BiologicsInflammatory Bowel Diseases, 2015
- Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel DiseaseJAMA, 2014
- Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2014
- Risk Factors for Lymphoma in Patients with Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2013
- Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort studyGut, 2012
- Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel DiseaseGastroenterology, 2012
- Psoriasis associated with anti‐tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literatureAlimentary Pharmacology & Therapeutics, 2011
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010